Total Payments
$209,945
2024 Payments
$43,255
Companies
34
Transactions
762
Medicare Patients
2,208
Medicare Billing
$244,752
Payment Breakdown by Category
Other$185,512 (88.4%)
Food & Beverage$16,646 (7.9%)
Travel$6,226 (3.0%)
Consulting$1,300 (0.6%)
Education$261.08 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $185,512 | 62 | 88.4% |
| Food and Beverage | $16,646 | 678 | 7.9% |
| Travel and Lodging | $6,226 | 16 | 3.0% |
| Consulting Fee | $1,300 | 1 | 0.6% |
| Education | $261.08 | 5 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $194,985 | 349 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,648 | 39 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,113 | 17 | $0 (2023) |
| ViiV Healthcare Company | $1,600 | 1 | $0 (2019) |
| SANOFI PASTEUR INC. | $1,488 | 1 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,265 | 58 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $759.19 | 42 | $0 (2020) |
| Genentech USA, Inc. | $596.59 | 39 | $0 (2022) |
| Philips Electronics North America Corporation | $592.12 | 18 | $0 (2021) |
| Actelion Pharmaceuticals US, Inc. | $559.17 | 26 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43,255 | 42 | GlaxoSmithKline, LLC. ($42,931) |
| 2023 | $71,072 | 76 | GlaxoSmithKline, LLC. ($70,674) |
| 2022 | $31,110 | 40 | GlaxoSmithKline, LLC. ($30,912) |
| 2021 | $35,785 | 102 | GlaxoSmithKline, LLC. ($33,161) |
| 2020 | $16,290 | 109 | GlaxoSmithKline, LLC. ($15,052) |
| 2019 | $4,711 | 173 | ViiV Healthcare Company ($1,600) |
| 2018 | $2,100 | 113 | GlaxoSmithKline, LLC. ($717.29) |
| 2017 | $5,621 | 107 | AstraZeneca Pharmaceuticals LP ($2,080) |
All Payment Transactions
762 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: RESPIRATORY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $120.56 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $112.70 | General |
| Category: RESPIRATORY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 11/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: RESPIRATORY | ||||||
| 10/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | In-kind items and services | $552.75 | General |
| Category: RESPIRATORY | ||||||
| 10/02/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
| 09/30/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 09/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | In-kind items and services | $916.63 | General |
| Category: RESPIRATORY | ||||||
| 09/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $136.09 | General |
| Category: RESPIRATORY | ||||||
| 09/23/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 09/18/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $311.16 | General |
| Category: RESPIRATORY | ||||||
| 09/12/2024 | Globus Medical, Inc. | COALITION (Device) | Food and Beverage | In-kind items and services | $255.82 | General |
| Category: Spine/Spine Surgery | ||||||
| 08/27/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $79.20 | General |
| Category: RESPIRATORY | ||||||
| 08/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: RESPIRATORY | ||||||
| 08/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,550.00 | General |
| Category: RESPIRATORY | ||||||
| 08/13/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: RESPIRATORY | ||||||
| 07/12/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $72.71 | General |
| 07/12/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $40.25 | General |
| 07/12/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $18.41 | General |
| 07/11/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $270.07 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 133 | 165 | $50,460 | $14,106 |
| 2022 | 4 | 194 | 215 | $117,825 | $23,562 |
| 2021 | 8 | 678 | 773 | $417,995 | $83,226 |
| 2020 | 14 | 1,203 | 1,363 | $571,693 | $123,859 |
Total Patients
2,208
Total Services
2,516
Medicare Billing
$244,752
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 111 | 140 | $40,540 | $11,354 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 25 | $9,920 | $2,752 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 120 | 139 | $36,140 | $10,817 | 29.9% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 11 | 11 | $24,585 | $6,630 | 27.0% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2022 | 45 | 45 | $49,500 | $3,727 | 7.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 20 | $7,600 | $2,387 | 31.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 275 | 360 | $93,600 | $28,180 | 30.1% |
| 95810 | Sleep monitoring of patient (6 years or older) in sleep lab | Office | 2021 | 32 | 32 | $71,520 | $19,767 | 27.6% |
| 95806 | Unattended sleep study with recording of heart rate, oxygen, respiratory airflow and effort | Office | 2021 | 159 | 163 | $179,300 | $16,021 | 8.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 77 | 77 | $44,660 | $11,573 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 31 | $11,780 | $3,629 | 30.8% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 64 | 68 | $8,840 | $1,808 | 20.5% |
| 94729 | Measurement of lung diffusing capacity | Office | 2021 | 21 | 21 | $4,200 | $1,200 | 28.6% |
| 94726 | Determination of lung volumes using plethysmography | Office | 2021 | 21 | 21 | $4,095 | $1,049 | 25.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 410 | 553 | $143,780 | $37,444 | 26.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 229 | 229 | $132,820 | $34,403 | 25.9% |
| 95806 | Unattended sleep study with recording of heart rate, oxygen, respiratory airflow and effort | Office | 2020 | 140 | 142 | $156,200 | $15,334 | 9.8% |
| 95810 | Sleep monitoring of patient (6 years or older) in sleep lab | Office | 2020 | 26 | 26 | $58,110 | $15,139 | 26.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 55 | 60 | $22,800 | $5,371 | 23.6% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2020 | 128 | 134 | $17,420 | $4,383 | 25.2% |
| 94729 | Measurement of lung diffusing capacity | Office | 2020 | 66 | 68 | $13,600 | $3,616 | 26.6% |
| 94726 | Determination of lung volumes using plethysmography | Office | 2020 | 66 | 68 | $13,260 | $3,394 | 25.6% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2020 | 15 | 15 | $4,500 | $1,425 | 31.7% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 15 | 15 | $4,050 | $1,403 | 34.6% |
| 90662 | Vaccine for influenza for injection into muscle | Office | 2020 | 15 | 15 | $1,775 | $914.70 | 51.5% |
About Dr. Lawrence Shulman, MD
Dr. Lawrence Shulman, MD is a Pulmonary Disease healthcare provider based in Lake Success, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265471585.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence Shulman, MD has received a total of $209,945 in payments from pharmaceutical and medical device companies, with $43,255 received in 2024. These payments were reported across 762 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($185,512).
As a Medicare-enrolled provider, Shulman has provided services to 2,208 Medicare beneficiaries, totaling 2,516 services with total Medicare billing of $244,752. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Lake Success, NY
- Active Since 06/05/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1265471585
Products in Payments
- AREXVY (Drug) $85,494
- TRELEGY ELLIPTA (Drug) $62,000
- ANORO ELLIPTA (Drug) $3,933
- BEVESPI AEROSPHERE (Drug) $2,035
- BELSOMRA (Drug) $1,962
- NUCALA (Biological) $1,492
- ANORO (Drug) $442.51
- Xolair (Biological) $417.24
- OFEV (Drug) $379.97
- Yupelri (Drug) $376.18
- STIOLTO RESPIMAT (Drug) $363.55
- DUPIXENT (Biological) $321.63
- STIOLTO (Drug) $319.15
- BREO (Drug) $309.86
- SMARTVEST (Device) $303.29
- LONHALA MAGNAIR (Drug) $297.41
- Respiratoriy Care Undiv (Device) $258.86
- COALITION (Device) $255.82
- BROVANA (Drug) $234.66
- PREVNAR - 13 (Biological) $224.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.